|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits in other banks | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Available-for-sale debt securities, at fair value | ||||||||||||||||||||
| Equity securities, at fair value | ||||||||||||||||||||
| Total restricted securities, at cost | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans and leases, net of allowance for loan and lease losses of $14,193 and $12,416 | ||||||||||||||||||||
| Loans and leases, net of allowance for credit losses of $12,455 and $11,986 | ||||||||||||||||||||
| Bank premises and equipment, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Net deferred tax assets | ||||||||||||||||||||
| Other Assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Demand (non-interest bearing) | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Borrowed funds: | ||||||||||||||||||||
| Federal Reserve Discount Window advances | ||||||||||||||||||||
| Federal Home Loan Bank of Pittsburgh advances | ||||||||||||||||||||
| Junior subordinated debentures | ||||||||||||||||||||
| Total borrowed funds | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Other Liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Preferred shares ($1.25 par) Authorized: 20,000,000 shares at March 31, 2024 and December 31, 2023 Issued and outstanding: 0 shares at March 31, 2024 and December 31, 2023 | ||||||||||||||||||||
| Common shares ($1.25 par) Authorized: 50,000,000 shares at March 31, 2024 and December 31, 2023 Issued and outstanding: 19,795,151 shares at March 31, 2024 and 19,787,031 shares at December 31, 2023 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
